Stance Capital’s AbbVie ABBV Stock Holding History

Stance Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Sell	6,147 -93	-1%	-$20.6K	0.65%	66
2025 Q4	$1.43M	Buy	6,240 +86	+1%	+$19.6K	0.52%	56
2025 Q3	$1.42M	Sell	6,154 -647	-10%	-$132K	0.52%	55
2025 Q2	$1.26M	Buy	+6,801	New	+$1.26M	0.47%	127
2025 Q1	–	Sell	-9,652	Closed	-$1.72M	–	47
2024 Q4	$1.72M	Buy	+9,652	New	+$1.77M	1.06%	33

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stance Capital's ABBV Position: Q1 2026 in Review

Stance Capital reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $20.6K and leaving 6,147 shares worth $1.34M. The position accounts for 0.65% of the portfolio, ranked #66.

Stance Capital first reported a position in ABBV in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.72M in Q4 2024. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Stance Capital held 6,147 shares of AbbVie worth $1.34M as of Q1 2026.
Stance Capital sold 93 AbbVie shares in Q1 2026, an estimated $20.6K.
AbbVie made up 0.65% of Stance Capital's portfolio in Q1 2026, its #66 holding.
Stance Capital first reported a position in AbbVie in Q4 2024 and has held it in 5 quarters since.
Stance Capital's AbbVie position peaked at $1.72M in Q4 2024.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.